Conflict of Interest at the Intersection of Business and Healthcare Values: 2002-2007

We welcome contributions to this Bibliography. We are especially interested in items which focus on the Canadian context. If there are any items that are missing which you think should be there, please email references to healthandbusiness@cbern.ca .

Bioethicsline (Publication., from Kennedy Institute of Ethics for the National Library of Medicine (NLM): http://www.georgetown.edu/research/nrcbl/

Scope Note Series. Kennedy Institute of Ethics Journal. Washington, DC: National Reference Center for Bioethics Literature.

Ethical Issues in Managed Health Care Organizations.  (1999).). Washington, DC: Woodstock Theological Center.

Code of Federal Regulations, Title 42 - Public Health, Ch 1, Part 50, Susection F - Responsibility of Applicants for Promoting Objectivity in Research for Which PHS Funding is Sought. (2000). Retrieved. from http://grants.nih.gov/grants/compliance/42_CFR_50_Subpart_F.htm.

HHS Direction Needed to Address Financial Conflicts of Interest. (2001). Retrieved. from http://www.gao.gov/.

Protecting Subjects, Preserving Trust, Promoting Progress: Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research.  (2001).). Washington, DC: Association of American Medical Colleges.

Report on Individual and Institutional Financial Conflict of Interest.  (2001).). Washington, D.C.: Association of American Universities.

Protecting Subjects, Preserving Trust, Promoting Progress II: Principles and Recommendations for Oversight of an Institution's Financial Interests in Human Subjects Research.  (2002).). Washington, DC: Association of American Medical Collages.

American Society of Clinical Oncology: Revised Conflict of Interest Policy. (2003). Journal of Clinical Oncology, 21(12), 3.

Chaoulli v. Quebec (Attorney General), 35 (SSC 2005).

Anderlik, M. R. (2001). The Ethics of Managed Care: A Pragmatic Approach. Bloomington: Indiana University Press.

Anders, G. (1996). Health Against Wealth. Boston: Houghton Mifflin Company.

Angell, M. (2004). The Truth about Drug Companies: Random House.

Angell, M. (2004). The truth about drug companies: How they decive us and what to do about it: Random House.

Annas, G. J. (1990). Outrageous fortune: selling other people's cells. (analysis of the John Moore v. Regents of the University of California case). Hastings Center Report, 20(6), 36.

Annas, G. J. (1995). Sex, money, and bioethics: watching ER and Chicago Hope.(Emergency Room, popular television series). Hastings Center Report, 25(5), 40.

Annas, G. J. (1998). Some Choice: Law, Medicine & the Market. Oxford: Oxford University Press.

Annas, G. J. (2004). American Bioethics: Crossing Human Rights and Health Law Boundaries Oxford: Oxford University Press.

Arendt, H. (2000). The Concept of History, Ancient and Modern. In P. Baehr (Ed.), The Portable Hannah Arendt. New York: Penguin Group (USA) Inc.

Astor, A., and Sreenivasan, G. (2003). Providing free care to the uninsured: how much should physicians give? Annals of Internal Medicine, 139(9), Nov 4.

Attaran, A. (2004). How Do Patents and Economic Policies Affect Access to Essential Medicines in Developing Countries. Health Affairs, 23(3), 155-166.

Aumann, G., and T. H. Murray. (1986). Striking a Moral Balance in Worksite Screening. Busines and Health, 10, 10-12.

Barlow, M. (2003). Profit is Not the Cure: A Citizen's Guide to Saving Medicare Toronto: McClelland & Stewart.

Basheer, S. (2007). India's New Paatent Regime: Aiding 'Access' or Abettign 'Genericide'? International Journal of Technology and Globalization.

Becker, L. C., and Charlotte B. Becker (Ed.). (1992). Encyclopedia of Ethics (Vol. 2). New York: Garland.

Belsky, L., Lie, R., Mattoo, J., Emanuel, E. J., and Sreenivasan, G. (2004). The general agreement on trade in services: implications for health policymakers. Health Affairs, 23(3), 137-145.

Bensimon, C. M., and Benatar, Solomon R. (2006). Developing Sustainability: A New Metaphor for Progress. Theoretical Medicine and Bioethics, 27(1), 59-79.

Blumenthal, D., N. Causino, E. Campbell and K.S. Louis. (1996). Relationships between academic institutions and industry in the life sciences--an industry survey. New England Journal of Medicine, 334(6), 5.

Boyd, E. A., M.K. Choand and L.A. Bero. (2003). Financial Conflict-of-Interest Policies in Clinical Research: Issues for Clinical Investigators. Academic Medicine, 78(9), 769-774.

Brown, K. (2000, July). The Human Genome Business Today. Scientific America, 283, 50-55.

Buchanan, A., Norman Daniels, et al. (2000). From Chance to Choice:Genetics and Justice. New York and Cambridge: Cambridge University Press.

Buchanan, A., and DeCamp, Matthew (2006). Responsibility for Global Health. Theoretical Medicine and Bioethics, 27(1), 95-114.

Cahill, L. S. (2004). Bioethics and the Common Good. Milwaukee, WI: Marquette University Press.

Callahan, D. (1975). Morality in Management. Chicago: Center for Health Administration Studies, University of Chicago.

Callahan, D. (1983, February 16). Fixed Fees Prove Disastrous in Practice. USA Today.

Callahan, D. (1984). The Humanities and Public Policy. In R. S. French, and J.D. Moreno (Ed.), The Public Humanities Washington, DC: George Washington University.

Callahan, D. (1986). Commentary on "No Room in the Marketplace: Health Care for the Poor". Health Progress, December.

Callahan, D. (1986). Ethics and Health Care Cost Education. In R. D. Cunningham (Ed.), Medical Education: Making the Grade in Cost Containment. Battle Creek: W.K. Kellogg Foundation.

Callahan, D. (1986). Forces Driving Demand for Health Care Also Create Ethical Issues. Health Management Quarterly, Fall.

Callahan, D. (1989). Beyond Individualism: Bioethics and the Common Good. Second Opinion.

Callahan, D. (1989, December 10). How Much Health Care Can We Afford? The Washington Post.

Callahan, D. (1990). Modernizing Mortality: Medical Progress and the Good Society. Hasting Center Report.

Callahan, D. (1990). Rationing Medical Progress: The Way to Affordable Health Care. New England Journal of Medicine.

Callahan, D. (1994). Bioethics and the Common Good. Hasting Center Report.

Callahan, D. (1995). Caveat Emptor: A Response to John Maguire. Journal of the Medical Association of Georgia  

Callahan, D., and Ohilip Boyle. (1995). What Price Mental Health: Georgetown University Press.

Callahan, D. (1996). Controlling the Cost of Health Care for the Old: Fair Means and Foul. New England Journal of Medicine.

Callahan, D. (1996). Health Care and Community Obligation. Busines and Health.

Callahan, D. (1997). Equity and the Goals of Medicine: World Health Organization.

Callahan, D. (1998). The Future of the Medical Profession Between Bioethics and the Market. Medicine nei Secoli, 10(1).

Callahan, D. (1998). Viagra: What's at Stake? Bergen Record.

Callahan, D. (1999). Culture, Economics, and Alzheimer’s Disease. Journal of Applied Gerontology.

Callahan, D. (1999, March/April). Health and Wealth: Second Opinions. The Catholic Worker.

Callahan, D. (1999). Medicine and the Market: A Research Agenda. Journal of Philosophy and Medicine, 24.

Callahan, D. (1999, April 9). The Truth About Medicare. Commonweal.

Callahan, D. (2000). Job-Based Health Insurance: Who Has the Duty to Lead. Business and Health.

Callahan, D. (2000). Medicine and the Market. In J. Simek (Ed.), Health Care Reforms and Central and Eastern Europe Prague: Institute of Postgraduate Medical Education.

Callahan, D. (2002). How Much Medical Progress Can We Afford. Journal of Molecular Biology.

Callahan, D. (2003). How Much Medical Progress Can We Afford? Bioforum International.

Callahan, D. (2003). Individual Godd and Common Good. Perspectives in Biology and Medicine, 46(4).

Callahan, D. (2003). Put a Hold on Progress. Across the Board.

Callahan, D. (2003). Review of Francis Fukuyama's Or Posthuman Future. Pharos.

Callahan, D. (2003). Too Much of a Good Thing. Hastings Center Report.

Callahan, D. (2003). What Price Better Health? Hazards of the Research Imperative: University of California Press.

Callahan, D. (2004, March/April). Sustainable Medicine. Nepali Times.

Callahan, D. (2005). How Much Is Enough or Too Little? Assessing Health Care Demand in Developed Countries. Medicinal Chemistry II.

Callahan, D., and Angela Wasunna. (2006). Medicine and the Market: Equity v. Choice: Johns Hopkins Press.

Carrin, G. (2002). Social Health Insurance in developing countries: a continuing challenge. International Social Security Review, 55.

Castle, D., Cheryl Cline, Abdallah S. Daar, Charoula Tsamis, and Peter A. Singer. (2006). Science, Society, and the Supermarket: The Opportunities and Challenges of Nutrigenomics Wiley-Interscience  

CAULFIELD, T. A., BURGESS, M. M., WILLIAMS-JONES, B. BAILY, M-A.,  CHADWICK, R., CHO, M., DEBER, R., FLEISING, U., FLOOD, C., FRIEDMAN, J., LANK, R., OWEN, T., SPROULE, J. (2001). Providing Genetic Testing Through the Private Sector — A View From Canada. Isuma: The Canadian Journal of Policy Research 2(3), 74-81.

Caulfield, T. A., and Bryn Williams-Jones (Ed.). (2006). The Commercialization of Genetic Research - Legal, Ethical, and Policy Issues (1 ed.): Springer.

Childress, J. F., and Ruth D. Gaare (Ed.). (Issued annually with bimonthly updates since 1983). BioLaw. Frederick, MD: University Publications of America.

Clarkson, M. B. E. (Ed.). (1998). The Corporation And Its Stakeholders: Classic and Contemporary Readings. Toronto: University of Toronto Press.

Cook-Degan, R. (1994). The Gene Wars: Science, Politics, and the Human Genome. New York: W. W. Norton.

Cragg, W. (2005). Ethics and Business in the New Age of Globalization:  Creating a Collaborative Business Ethics Research Network. from http://www.yorku.ca/csr/EthicsResearchNetwork/index.html

Cramer, M. P., and S.R. Saks. (1994). Translating safety, efficacy and compliance into economic value for controlled release dosage forms. PharmacoEconomics, 5(6), 482-504.

Crigger, B.-J. (1988). Perish for publishing? (research fraud). Hastings Center Report, 18(5), 4.

Crigger, B.-J. (1991). A generation at risk. (report on state of adolescent health care and health insurance coverage from the Office of Technology Assessment recommends improvements). Hastings Center Report, 21(3), 3.

Crigger, B.-J. (1991). The Research Freedom Act. (act introduced in Congress that would overturn the moratorium on federal funding of fetal tissue transplantation). Hastings Center Report, 21(1), 2.

Crigger, B.-J. (1991). You can't always get what you want. (biomedical research allocations: recommendations from the Institute of Medicine). Hastings Center Report, 21(1), 3.

Crigger, B.-J. (2006). e-medicine: policy to shape the future of health care. Hastings Center Report, 36(1), 12.

(top)

Daar, A. S. (2002). The science of stem cells: some implications for law and policy.(Canada). Health Law Review, 11(1), 5.

Daniels, N., and James Sabin. Setting Limits Fairly: Can We Learn to Share Medical Resources (1st ed.). New York: Oxford University Press, USA.

Darr, K. (1991). Ethics in Health Services Management. Baltimore: Health Professions Press.

Darr, K. (1997). Ethics in Health Services Management. Baltimore: Health Professions Press.

Davies, K. (2001). Cracking the Genome: Inside the Race to Unlock Human DNA. New York: Free Press.

Debine, K. (2000). NIH Lifts Stem Cell Funding Ban, Issues Guidelines. The Scientist, 14(1), 8.

Dhanda, R. K. (2002). Guiding Icarus: Merging Bioethics with Corporate Interests: Wiley.

Dolgin, J. L., and Lois L. Shepherd. (2005). Bioethics and The Law. New York: Aspen Publishers.

Donaldson, T., and Thomas W. Dunfee. (1999). Ties That Bind. Boston, Massachusetts: Harvard Business School Press.

Duncan, A. S., G.R. Dunstan, and R.B. Welborn (Ed.). (1981). Dictionary of Medical Ethics. New York: Crossroad.

Eaton, M. L. (2004). Ethics and the Business of Bioscience. Stanford: Stanford University Press.

Ehringhaus, S., and David Korn. (2004). U.S. Medical School Policies on Individual Financial Conflicts of Interest Results of an AAMC Survey. Washington, DC: Association of American Medical Colleges. .

Engelhardt, H. T. (1986). The Foundations of Bioethics: Oxford University Press.

Evans, A. R. (1999). Redeeming Marketplace Medicine: A Theology of Health Care New York: Pilgrim Press.

Farmer, P. (2001). Infections and Inequalities: The Modern Plagues (1 ed.). London: University of California Press.

Farmer, P. (2003). Pathologies of Power: Health, Human Rights, and the New War on the Poor (1 ed.). London: University of California Press.

Farmer, P., Margaret Connors & Janie Simmons (Ed.). (2007). Women, Poverty and AIDS: Sex, Drugs and Structural Violence (2 ed.). Monroe, ME: Common Courage Press.

Fears, R., Derek Roberts, et al. (2000). National or Rationed medicine? The Promise of Genetics for Improved Clinical Practice. British Medical Journal, 320, 933-935.

Ferris LE, S. P., Naylor CD. (2004). Better governance in academic health sciences centres:  moving beyond the Oliveri/Apotex Affair in Toronto. Journal of Medical Ethics, 30, 25-29.

Filmer, D. P., L. (1999). The Impact of public spending on health: does money matter? : World Bank.

Finegold, D. L. B., Cecile M.  Daar, Abdallah S.  Eaton, Margaret L.  Godard Bartha, Beatrice  Knoppers, Maria  Mackie, Jocelyn  and Singer, Peter A. (2005). BioIndsustry Ethics. Burlingtion, MA: Elsevier Academic Press.

Fogel, R. (2004). Health, Nutrition,and Economic Growth. Economic Development& Cultural Change, 53(3).

French, R. S., and J.D. Moreno (Ed.). (1984). The Public Humanities. Washington, DC: George Washington University.

Fried, S. (1999). Bitter Pills: Inside the Hazardous World of Legal Drugs. New York: Bantam Books.

Friedman, M. (1987). The Social Responsibility of Business is to Increase its Profits. In D. P. a. W. Waluchow (Ed.), Business Ethics in Canada. Scarborough: Prentice-Hall.

Fuchs, V. R. (1998). Who Shall Live? (Health, Economics, and Social Choice). Hackensack: World Scientific Publishing Comp nay.

Fukuyama, F. (1992). The End of History and the Last Man. London: Penguin Books.

Fukuyama, F. (2002). Our Posthuman Future: Consequences of The Biotechnology Revolution. New York: Picador.

Galiani, S., P. Gerther and E. Schargrodsky. (2002). Water of life: the impact of the privatization of water services on child mortality. Stanford: Stanford Institute for Economic Policy Research (SIEPR), Stanford University.

Gambardella, A., L. Orsenigo and P. Pammolli. (2000). Global competitveness in pharmaceuticals: a European Perspective. Retrieved. from.

Gibson, J. L., D.K. Martin, P. A., Singer. (2005). Evidence, economics and Ethics: Resource Allocation in Health Services Organizations. Healthcare Quarterly, 8, 50-59.

Gill, S., and Bakker, Isabella. (2006). New Constitutionalism and the Social Reproduction of Caring Institutions. Theoretical Medicine and Bioethics, 27(1), 35-57.

Gross, G. S. (2000). Federally Funding Human Everyone Stem Cell Research: An Administrative Analysis. Wisconsin Law Review(4), 855-884.

Gutmann, A., and Dennis Thompson. (1996). Democracy and Disagreement. Cambridge, MA: Belknap Press.

Halverson, P. K., Arnold D. Kaluzny, Curtis P. McLaughlin and Glen P. Mays. (1998). Managed Care and Public Health. Gaitherburg, MD: Aspen.

Hannibal, K., and Robert Lawernce. (1999). The Health Professional as Human Right Promoter: Ten Years of Physicians for Human Rights (USA). In J. M. Mann, Sofia Gruskin, Michael A Grodin, George J. Annas (Ed.), Health and Human Rights (pp. 404-416). New York: Rutledge.

Haslberger, A. G. (2000). Monitoring and Labeling for genetically Modified Products. Science, 287, 431-432.

Henry, D., and J. Lexchin. (forthcoming). Industry as a medicines provider. The Lancet.

Hirschman, A. O. (2006). Exit, Voice, and Loyalty: Responses to Decline in Firms, Organizations, and States Cambridge, MA: Harvard University Press.

Holtug, N. (2001). Greating and patening new life forms. In H. P. S. Kuhse (Ed.), A Companion to Bioethics (pp. 528). Boston: Blackweill Publishing Professional.

Howard, K. (2000, July). The Bioinformatics Gold Rush. Scientific American, 283, 58-63.

Hubbard, T., and J. Love. (2004). A New Trade Frameworkd for Global Healthcare R&D. PLoS Biology, 2(3), 147-150.

Huttinger, L. F. (Ed.). (Published monthly 1975-1989; quarterly 1990 - present). New Titles in Bioethics. Washington, DC: National Reference Center for Bioethics Literature.

(top) 

Ijsselmuiden, C., and Ruth Raden. (1999). Research and Infored Consent in Africa -- Another look. In J. M. Mann, Sofia Gruskin, Michael A Grodin, George J. Annas (Ed.), Health and Human Rights (pp. 363-372). New York Rutledge.

Jennings, B. Duties and Responsibilities of Not-for-Profit Hospital trusteship EthicalIsues in Turbulent Times. Unpublished Workshope Presentation. The Hastings Center.

Jennings, B. (2002). Ethics & Trusteeship for Health Care Hospital Board Service in Turbulent Times. Hastings Center Report, Special Supplement.

Johnstone, J., and Carl Elliott. (2003). Identity and Genetic Ancestry Tracing. Developing World Bioethics 2003, 3(2).

Johnstone, J. (2004). When Money Talks and Science Listens.  (Review of Marcia Angell’s The Truth About the Drug Companies: How They Deceive Us and What To Do about It and Sheldon Krimsky’s Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research?). Hastings Center Report, 34(5), 44-45.

Johnstone, J. (2005). It's Not about the Money. Hastings Center Report, 35(2).

Johnstone, J., and A.A. Wasunna. (2006). Patents, Biomedical Research, and Treatments: Examining Concerns, Canvassing Solutions. Hastings Center Report.

Johnstone, J. (2006). Paying Egg Donors: Exploring the Arguments. Hastings Center Report, 36(1), 28-31.

Johnstone, J. (2007). Health Related Academic Technology Transfer: Rethinking Patenting and Licensing Practices. International Journal of Technology and Globalization  

Kennedy, D. L., and Margaret L. Eaton. (2007). Innovation in Medical Technology: Ethical Issues and Challenges. Baltmore: The Johns Hopkins University Press.

Kilner, J. F., Robert D. Orr and Judith Allen Shelly (Ed.). (1998). The Changing Face of Health Care: A Christian Appraisal of Managed Care, Resource Allocation, and Patient-Caregiver Relationships. Grand Rapids, MI: William B. Eerdmans and Carlisle,.

Koivusalo, M. (2006). The Impact of Economic Globalisation on Health. Theoretical Medicine and Bioethics, 27(1), 13-34.

La Puma, J. (1998). Managed Care Ethics: Essays on the Impact of Managed Care on Traditional Medical Ethics. New York: Hatherleigh Press.

Lanjouw, J. (1998). The introduction of pharmaceutical product patent sin India: hart less exploitation of the poor and suffering? : NBER.

Lappe, M., and Britt Bailey. (1998). Against the Grain: Biotechnology and the Corporate Takeover of Your Food. Monroe, ME: Common Courgare Press.

Lavery, J. V., Christine Grady, Elizabeth R. Wahl, EzekielJ. Emanuel (Ed.). (2007). Ethical Issues in International Biomedical Research: A Casebook New York: Oxford University Press, USA.

Lexchin, J. (2000). Click, click: the internet and prescription drugs. Australian Prescriber(23), 73-74.

Lexchin, J. (2001). Interactions between doctors and pharmaceutical sales representatives. Canadian Journal of Clinical Pharmacology, 8, 64-65.

Lexchin, J. (2001). Lifestyle drugs: issues for debate. Canadian Medical Association Journal(164), 1449-1451.

Lexchin, J. (2001). A national pharmacare plan: combining efficiency and equity. Ottawa: Canadian Centre for Policy Alternatives.

Lexchin, J. (2001). Pharmaceuticals: politics and policy. In P. Armstrong, H. Armstong, and D. Coburn (Ed.), Unhealthy times: political economy perspectives on health and care in Canada (pp. 31-44). Toronto: Oxford University Press.

Lexchin, J. (2001). Profits first:  the pharmaceutical industry in Canada. In B. S. Bolaria, and H. Dickinson (Ed.), Health, illness, and health care in Canada (2nd ed.). Toronto: Nelson.

Lexchin, J. (2001). Trade deals and drugs:  heads industry wins, tails Canada loses: Canadian Centre for Policy Alternatives.

Lexchin, J., Lisa A. Vero, Benjamin Djulbegovic, and Otavio Clark. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal, 326, 1167-1170.

(top)

MacDonald, C. (2002). Commercialization of Genetic Services: the Role of Genetic Counselors. Human Reproduction and Genetic Ethics, 8(1), 1-3.

MacDonald, C. (2002). Corporate Governance and Biotech-Ethics. Paper presented at the Canadian Bioethics Society 14th Annual Conference  

MacDonald, C., and Bryn Williams-Jones. (2002). Ethics and Genetics: Susceptibility Testing in the Workplace. Journal of Business Ethics, 35(3), 235-241.

MacDonald, C. (2002). Stem Cell Ethics and the Forgotten Corporate Context. American Journal of Bioethics, 2(1).

MacDonald, C., and Rahul K. Dhanda. (2003). Ethics in Biotechnology – An Executive Guide  Unpublished Paper.

MacDonald, C. (2003). Patents and Benefit-Sharing as a Challenge for Corporate Ethics. In i. B. M. Knoppers (Ed.), Populations and Genetics: Legal and Socio-Ethical Perspectives: Martinus Nijhoff Publishers.

MacDonald, C. (2004, April 8). Bioscience corporations must do better at corporate ethics. BioScience News & Advocate.

MacDonald, C. (2004). Business Ethics 101 for the Biotech Industry. Biodrugs, 18(2), 71-77.

MacDonald, C., and Melissa Whellams. (2005). Corporate Ethics and GM Food Labeling. from http://www.6degrees.ca/e-newsletters/e-news0501.html#article

MacDonald, C. (2006). The Precautionary Principle and the Ethics of Corporate Decision Making. Paper presented at the Canadian Society for the Study of Practical Ethics annual meeting from http://www.biotechethics.ca/.

MacDonald, C. (2007). Corporate Decisions about Labeling Genetically Modified Foods. Journal of Business Ethics, 74(4).

Machan, D., and Luisa Kroll. (1996, August 12). An Agreeable Affliction. Forbes, 148.

Mahmudi-Azer, S. (2006). Arms Trade and its Impact on Global Health. Theoretical Medicine and Bioethics, 27(1), 81-93.

Mann, J. M., Sofia Gruskin, Michael A Grodin, George J. Annas (Ed.). (1999). Health and Human Rights. New York: Routledge.

Marcuse, H. (1964). One Dimensional Man. Boston: Beacon.

Maskus, K. (2000). Intellectual Property in the global economy. Washington DC: Institute for International Economics.

Maskus, K. (2002). Ensuring Access to Essential Medicines: Some Economic Considerations. Specialty law digest. Health care law, 291, 9-25.

Maternowska, M. C., and Paul Farmer. (2006). Reproducing Inequities: Poverty And the Politics of Population in Haiti (Studies in Medical Anthropology). New Brunswick, NJ: Rutgers University Press.

McArthur, W. (1999). Intellectual Property Rights and Pharmaceutical Industry. Vancouver: The Fraser Institute.

Menon, D. (2001). Pharmaceuticals cost control in Canada: Does it work? Health Affairs, 20(3), 92-103.

Miller, F. H. (2002). Rights Resources. Aldershot, Hants/Burlington, VT: Ashagte.

Miller, H. I. (1994). A Need to Reinvent Biotechnology Regulations at the EPA. Science, 266, 1815-1819.

Miller, H. I. (1999). A Rational Approach to Labeling Biotech-Derived Foods. Science, 284, 1471-1472.

Miller, H. I., and Gregory Conko. (2000). The Science of Biotechnology Meets the Politics of Global Regulations. Issues in Science and Technology, 17, 47-54.

Moran, M., A. Ropars, J. Guzman, J. Diaz, and C. Garrison. (2005). The new landscape of neglected disease drug development. London: LSE pharmaceutical R&D policy project, Wellcome Trust.

Moreno, J. D. (1995). Deciding Together: Bioethics and Moral Consensus. New York: Oxford University Press, USA.

Morris, J., R. Mowatt, and W. Reekie. (2001). Ideal Matter: Globalisation and the Intellectual Property Debate. New Delhi: Liberty Institute.

Moynihan, R. A. C. (2005). Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. New York: National Books.

Murray, T. H. (1982). Genetic Screening of Workers for Susceptibility to Workplace Hazards Poses Ethical Questions. Genetic Engineering News(November/December), 1.

Murray, T. H. (1983, August). Buying Health. The News, 1.

Murray, T. H. (1983). Warning: Screening Workers for Genetic Risk. Hastings Center Report, 5-8.

Murray, T. H. (1985). Basic Research, Government Support & the Public Good. Genetic Engineering News, 5, 31.

Murray, T. H. (1985). Genetic Testing at Work:  How Should It Be Used? Technology Review, 51-59.

Murray, T. H. (1985). Lethal Paradox in Occupational Health Research. Business and Society Review, 20-24.

Murray, T. H. (1986). Cancer Research for Profit:  Some Ethical Qualms. Genetic Engineering News, 32,38.

Murray, T. H. (1986). Public Trust in Biotechnology:  A Threatened Resource. Genetic Engineerign News, 29.

Murray, T. H. (1987). On the Human Body as Property:  The Meaning of Embodiment, Markets, and the Needs of Strangers. University of Michigan Journal of Law Reform, 20(4), 1055-1088.

Murray, T. H. (1991). Genetics, Ethics, and Health Insurance: Office of Technology Assessment.

Murray, T. H. (1993). Genetic Information and Health Insurance: Task Force on Genetic Information and Insurance, NIH/DOE Working Group on Ethical, Legal, and Social Implications of Human Genome Research.

Murray, T. H. (1996). The Genome and Access to Health Care:  Two Ethical Issues. In T. H. Murray, M. Rothstein, and R. Murray (Ed.), The Genome and the Future of Health Care (pp. 209-223): Indiana University Press.

Murray, T. H., M. Rothstein and R.F. Murray (Ed.). (1996). The Genome and the Future of Health Care: Indiana University Press.

Murray, T. H. (1997). Genetic Discrimination in Health Insurance and Why It Is Wrong. In E. a. W. S. Smith (Ed.), Plain Talk About the Human Genome Project (pp. 159-168): Tuskeegee University.

Murray, T. H. (1997). Money-Back Guarantees for IVF:  An Ethical Critique. Journal of Law, Medicine & Ethics, 292-294.

(top)

Nelkin, D., and Emily Marden. (1999). Cloning: A Business without Regulations. Hofstra Law Review, 27, 569-578.

Network, I. P. (2006). Civil Society Report on Intellectual Property, Innovation and Health London: International Policy Network.

Nkrumah, Y. K., and P.L. Osewe. (2007). TRIPS Compliance and Public Health: Opportunities and Obstacles for African Countries. International Journal of Technology and Globalization.

Olson, M. (1971). The Logic of Collective Action: Public Goods and the Theory of Groups. Cambridge, MA: Harvard University Press.

O'Neill, O. (2002). Autonomy and Trust in Bioethics. Cambridge: Cambridge University Press.

O'Neill, O. (2002). Public health or clinical ethics: thinking beyond borders. Ethics & International Affairs, 16(2), 35.

Over, M. (1991). Economics for health sector analysis: concepts and cases: Economic Development Institute, World Bank.

Pearson, S. D., James Sabin, Ezekiel J. Emanuel. (2003). No Margin, No Mission: Health Care Organizations and the Quest for Ethical Excellence New York: Oxford University Press, USA.

Peterson, C. L. (2004). Taming the Sharks: Towards a Cure for the High-Cost Credit Market. Akron: University of Akron Press.

Poff, D., and Wilfrid Waluchow (Ed.). (1987). Business Ethics in Canada. Scarborough: Prentice-Hall.

Posner, E. A., and Richanrd A. Posner. (1999). The Demand for Human Cloning. Hofstra Law Review, 27, 579-608.

Pritchett, L., and L. Summer. (1996). Wealthier is Healthier. Journal of Human Resources, 31(4), 841-868.

Ramiah, I., and M. Reich. (2005). Public-Private Partnerships and Entire Drugs for HIV/SIDS: Lessons from Botswana. Health Affairs, 24(2), 545-551.

Rawlins, M. (2004). Cutting the cost of drug developmnet? Nature, 3(360).

Reekie, D. W. (1997). How Competition Lowers the Cost of Medicines. Cuadernos de Derects Europeu Farmaceutico, 3(8), 35-48.

Reich, W. T. (Ed.). (1995). Encyclopedia of Bioethics (2nd ed.). New York: Macmillan.

Romanow. (2002). Building on Values: The Future of Health Care in Canada, Final Report of Commission on the Future of Health Care in Canada.

Ruse, M., and David Castle (Ed.). (2002). Genetically Modified Foods: Debating Biotechnology. Amherst, NY: Prometheus Books.

(top)

Sandel, M. J. (2003). What Money Shouldn't Buy. Hedgehog Review, Summer, 77-97.

Santoro. (2005). Ethics and the pharmaceutical industry: Cambridge University Press.

Sauer, C., and Robert M. Sauer. (2005). Reducing Barriers to the Development of High Quality, Low Cost Medicines: A Proposal for Reforming the Drug Approval Process London: International Policy Network.

Shapiro, H. T. (1997). Ethical and Policy Issues of Human Cloning. Science, 277, 195-197.

Shaw, R., and M. Ainsworth. (1995). Financing health services through user fees and distance: World Bank.

Shenk, D. (2000). Biocapitalism: What Price the Genetic Revolution? In M. Winston, and Edelbach, Ralph (Ed.), Society, Ethics, and Technology. Belmont, CA: Wadworth.

Sheremeta, L., and Abdallah S. Daar. (2004). The case for publicly funded research on the ethical, environmental, economic, legal and social issues raised by nanoscience and nanotechnology Health Law Review, 12(3), 74.

Simek, J. (Ed.). (2000). Health Care Reforms and Central and Eastern Europe. Prague: Institute of Postgraduate Medical Education.

Singer, P., and Helga Kuhsa (Ed.). (1999). Bioethics: An Anthology. Oxford: Blackwell.

Singer, P. A. (1991). How Green is Your Grass?  A Comparative Analysis of the U.S. and Canadian Health Care Systems. Humane Medicine, 7, 47-53.

Singer, P. A., and F.H. Lowy. (1992). Rationing, Patient Preferences and Cost of Care at the End of Life. Archives of Internal Medicine, 152, 478-480.

Singer, P. A. (2005). Harnessing Nanotechnology to improve global equity: the less industrialized countries are eager to play an early role in developing this technology; the global community should help them. Issues in Science and Technology, 21(4), 57.

Smith, E., and Wlater Sapp (Ed.). (1997). Plain Talk About the Human Genome Project, : Tuskeegee University.

Smith, R. D., H. Thorsteinsdóttir, A. Daar, E.R. Gold, and Singer. (2004). Genomics knowledge and equity:  a global public good: Genomics knowledge and equity:  a global public good.

Soderlund, N., and B. Hansl. (2000). Health Insurance in South Africa: an empirical analysis of trends in risk-pooling and efficiency following deregulation. Health Policy and Planning, 15(4), 378-385.

Solomon, R. (1992). Business Ethics Quarterly, 2(3), 317-339.

Sreenivasan, G. (2002). International justice and health: a proposal. Ethics & International Affairs, 16(2), 81-90.

Sreenivasan, G., and Benatar, Solomn. (2006). Challenges for Global Health in the 21st Century: Some Upstream Considerations. Theoretical Medicine and Bioethics, 27(1), 3-11.

Starr, D. (2000). Blood: An Epic History of Medicine and Commerce. New York: Harper Perennial.

Stevens, P. (2004). Diseases of poverty and the 10/90 Gap. London: International Policy Network.

Stevens, P. (2005). Free Trade for Better Health. London: InternationalPolicy Network.

Stevens, P. (2005). The Real Determinants of Health. London: International Policy Network.

Thorsteinsdóttir, H., A.S.Daar, R.D. Smith, and P.A. Singer. (2003). Genomics – A Global Public Good? The Lancet, 361, 891-892.

Trouiller, P., P. Olliaro, E. Toreele, J. Orbinski, R. Laing, and N. Ford. (2002). Drug Development for neglected diseases: a different market and a public-health policy failure. The Lancet, 359.

Vlassov, V., P. Mansfield, J. Lexchin, A. Vlassova. (2001). Do drug advertisements in Russian medical journals provide essential information for safe prescribing. Western Journal of Medicine, 174, 391-394.

(top)

Walser, B. L. (1998). Shared Technical Decision making and the Disaggregation of Sovereignty. Tulane Law Review, 72, 1597-1697.

Walters, L., and Tamar Joy Kahn (Ed.). (Issued annually since 1975). Bibliography of Bioethics. Washington, DC: Kennedy Institute of Ethics, Georgetown University.

Wasunna, A., and T.H. Murray. (2004). The Rise of Scientific Medicine: The Professional Responsibilities in Research. In S. Restivo (Ed.), Science, Technology, and Society. Oxford: Oxford University Press.

Wasunna, A. A. (2007). Brinkmanship and Compulsory Lisensing. International Journal of Technology and Globalization.

Werhane, P. H., and Edward R. Freeman (Ed.). (1997). The Blackwell Encyclopedic Dictionary of Business Ethics. New York: Blackwell.

Wertheimer, A. I., and Thomas M. Santella. (2005). Pharmocoevolution: the benefits of incremental innovation London: International Policy Network.

Whellams, M., and Chris MacDonald. (2005). Corporate Decisions and the Dual Democratic Deficit of GM Food Labelling. Paper presented at the Canadian Society for the Study of Practical Ethics.

Williams-Jones, B. (2001). Private genetic testing in Canada: a summary. Health Law Review, 9(3).

Williams-Jones, B. (2003). University-industry relations & some lessons from biotech. Canadian Chemical News, 55(4), 20.

Williams-Jones, B. (2004). Ethics and social responsibility in the life sciences.(Interfaces). Canadian Chemical News, 56(9), 11.

Williams-Jones, B. (2004). A spoonful of trust helps the nanotech go down. Health Law Review, 12(3), 10.

(top)